iSpecimen Inc., a technology-driven company operating within the Health Care sector, recently disclosed its financial results for the quarter ending December 31, 2025, during a routine financial conference on April 1, 2026. The company, which is listed on the Nasdaq and trades in USD, operates an online marketplace designed to connect researchers with specimen contributors, thereby streamlining the procurement and management of specimens to support global medical advancements.
For the most recent quarter, iSpecimen Inc. reported a loss per share of $0.74, a significant improvement from the $6.28 per share loss recorded in the corresponding period the previous year. Despite this improvement in per-share loss, the company’s revenue experienced a sharp decline, falling to $0.1 million, which represents a 96.6 percent decrease from the $1.5 million reported in the prior year’s quarter. This substantial drop in revenue underscores the challenges faced by the company in maintaining sales activity.
On an annual basis, iSpecimen Inc. recorded a loss per share of $2.28, compared to a much larger loss of $17.58 per share in the previous year. Revenue for the full year also saw a significant contraction, dropping to $1.93 million from $9.29 million in the prior year. These figures highlight a marked reduction in both profitability and sales activity for the company over the past year.
The company’s market capitalization stands at approximately $1,389,442, with a close price of $0.142 as of April 1, 2026. The 52-week high for the stock was $3.18, recorded on September 8, 2025, while the 52-week low was $0.138, noted on April 1, 2026. The price-to-earnings ratio is currently at -0.02, reflecting the company’s ongoing financial challenges.
iSpecimen Inc.’s financial performance indicates a period of significant contraction, with both profitability and sales activity experiencing notable declines compared to the previous year. As the company navigates these challenges, its focus on leveraging technology to facilitate connections within the medical research community remains a critical component of its strategy to drive future growth and support global medical advancements.
